Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Waste Data Preview
In 2023, Alnylam Pharmaceuticals conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards. The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Waste Recovered | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Hazardous Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Non-Hazardous Waste Disposed | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected waste data points. To access the complete dataset with full disclosures and structure, create a free account to purchase the full dataset.
Insights into Alnylam Pharmaceuticals's Waste Treatment Practices
In 2023, Alnylam Pharmaceuticals generated a total of 954 metric tonnes of waste.
Of this amount, 7.86% of Alnylam Pharmaceuticals's total waste generated was recovered through methods such as recycling, reuse, or composting, while 92.14% was disposed of through landfilling, incineration, or combustion.
Alnylam Pharmaceuticals's Waste Recovery Rate
How much of Alnylam Pharmaceuticals's waste is recycled or recovered?
In 2023, Alnylam Pharmaceuticals reported a total waste generation of 954 metric tonnes, of which 7.86% was recovered through recycling, reuse, or composting. This low recovery rate highlights limited waste diversion and suggests that Alnylam Pharmaceuticals may be relying more heavily on landfill or incineration, underscoring opportunities for stronger resource recovery initiatives.
Has Alnylam Pharmaceuticals reduced its environmental waste footprint over time?
Since 2021, Alnylam Pharmaceuticals's total waste generation increased by 13.98%, including a 72.51% increase in 2023, indicating a persistent upward trend that may reflect scaling operations, inefficiencies in resource use, or a lack of effective waste minimization practices.
Over the same period, Alnylam Pharmaceuticals's waste recovery rate declined by 68.52%, with a further 42.03% drop in 2023, underscoring a weakening in waste diversion performance and a potential drift away from circular waste strategies.
Overall, Alnylam Pharmaceuticals is generating more waste while simultaneously backsliding on recovery efforts, both in the short and long term. This dual negative trend raises concerns about the company’s waste management priorities and its alignment with sustainability goals.
Alnylam Pharmaceuticals’s Waste Recovery vs. Disposal Over Time
- Total Waste Disposed
- Total Waste Recovered
Insights into Alnylam Pharmaceuticals’s Generation of Hazardous and Non-Hazardous Waste
In 2023, Alnylam Pharmaceuticals generated a total of 954 metric tonnes of waste.
Of this amount, 57.23% of Alnylam Pharmaceuticals's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment. 42.56% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.
Alnylam Pharmaceuticals’s Hazardous vs Non-Hazardous Waste Over Time
- Total Non-Hazardous Waste Generated
- Total Hazardous Waste Generated
How Alnylam Pharmaceuticals reduced the environmental impact of its waste?
Since 2021, Alnylam Pharmaceuticals's total waste generation increased by 13.98%, including a 72.51% rise in 2023, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.
Over the same period, the share of hazardous waste in Alnylam Pharmaceuticals's total output increased by 8.38%, including a further 12.63% rise in 2023, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.
Overall, Alnylam Pharmaceuticals has seen a continuous rise in both total waste and hazardous waste over time, signaling a worsening environmental impact that may require urgent reassessment of material sourcing, production processes, or waste mitigation strategies.
How does Alnylam Pharmaceuticals treat its hazardous waste?
In 2023, Alnylam Pharmaceuticals reported that 546 metric tonnes of its total waste output were classified as hazardous. This represents 57.23% of its overall waste generation.
The company treated this hazardous waste using a combination of methods. Only 0.92% of hazardous waste was recovered, meaning the vast majority was treated through disposal methods such as landfilling or incineration. This raises concerns about the environmental and health risks associated with Alnylam Pharmaceuticals’s current hazardous waste practices.